IL1B and COVID-19: Therefore, patients on therapy with IL-1i should be encouraged not to discontinue the treatment during SARS-CoV-2 vaccination [18], given the risk of disease relapses and the possible additional increase of IL-1 if breakthrough infections by COVID-19 appear.